



2025 KNOWLEDGE-BASED HOME-STUDY CE FOR PHARMACISTS AND PHARMACY TECHNICIANS INCORPORATING ANTI-AMYLOID-B (AB) MONOCLONAL ANTIBODY THERAPIES INTO ALZHEIMER'S DISEASE MANAGEMENT

Speaker: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Dean and Professor, Pacific University School of Pharmacy, Hillboro, OR

Pharmacist Learning Objectives

Upon completion of this knowledge-based CE activity, the pharmacist will be able to do the following:

- Discuss currently available pharmacologic treatments for Alzheimer's disease
- Explain the role and place in therapy of FDA-approved anti-amyloid- β monoclonal antibodies in the treatment paradigm for Alzheimer's disease.
- Identify patient characteristics and clinical indicators to appropriately select candidates for anti-amyloid- β monoclonal antibody therapy.
- Review the risks, benefits, and administration protocols of FDA-approved anti-amyloid- β monoclonal antibodies to facilitate informed decision

Pharmacy Technician Learning Objectives

Upon completion of this knowledge-based CE activity, the pharmacy technician will be able to do the following:

- Discuss currently available pharmacologic treatments for Alzheimer's disease
- Describe the benefits of the current available treatments for Alzheimer's Disease, including anti-amyloid- β monoclonal antibodies
- Identify the type of patient that may be eligible to receive anti-amyloid- β monoclonal antibody treatment options
- List common adverse effects of anti-amyloid- β monoclonal antibodies for Alzheimer's disease

Accreditation Information:

ACPE UAN: 0122-0000-25-078-H01-P/T

CPE Credit Hours: 1.0 hours (0.1 CEU) of CE credit

Release Date: November 3, 2025

Expiration Date: November 3, 2028

Disclosure: Dr. Marvanova, the moderators and the planners for this activity have no relevant financial relationship(s) with ineligible companies to disclose.

Sponsorship: This program is conducted solely by Premier and has no commercial or non-commercial support or sponsorship.

To participate and obtain CE credit, participants must complete the following steps:

1. Log on to Premier's CE website to register for the activity under "Home Study CE"
2. View and listen to the recorded activity
3. Complete both the post-test learning assessment questions and the activity evaluation within 45 days of the event.

[Click here](#) to view CE webinar system requirements for the learner to complete the online activity, including the internet browser(s) supported and minimum versions of each, and the minimum memory, storage, processor, and internet.

Note: CPE participation will be provided to CPE Monitor if the participant attains a passing grade of 70% or better on the post-test learning assessment questions. NABP e-profile ID number and birthdate (MMDD) must be provided by participants to receive CE credit.



Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This CE activity is provided as a free, value-added service to Premier health-system pharmacy staff.

For any questions regarding the CE activity, please contact [Premier's Pharmacy Team](#).

**2025 KNOWLEDGE-BASED HOME-STUDY CE
FOR PHARMACISTS AND PHARMACY TECHNICIANS
INCORPORATING ANTI-AMYLOID-B (AB) MONOCLONAL ANTIBODY THERAPIES
INTO ALZHEIMER'S DISEASE MANAGEMENT**

Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP

Dean and Professor
Pacific University School of Pharmacy
Hillboro, OR

ACPE UAN: 0122-0000-25-078-H01-P/T

CPE Credit Hours: 1.0 hour (0.1 CEU)

PHARMACIST LEARNING OBJECTIVES

Upon completion of this CE activity, the participant will be able to do the following:

- Discuss currently available pharmacologic treatments for Alzheimer's disease
- Explain the role and place in therapy of FDA-approved anti-amyloid- β monoclonal antibodies in the treatment paradigm for Alzheimer's disease.
- Identify patient characteristics and clinical indicators to appropriately select candidates for anti-amyloid- β monoclonal antibody therapy.
- Review the risks, benefits, and administration protocols of FDA-approved anti-amyloid- β monoclonal antibodies to facilitate informed decision

PHARMACY TECHNICIAN LEARNING OBJECTIVES

Upon completion of this CE activity, the participant will be able to do the following:

- Discuss currently available pharmacologic treatments for Alzheimer's disease
- Describe the benefits of the current available treatments for Alzheimer's Disease, including anti-amyloid- β monoclonal antibodies
- Identify the type of patient that may be eligible to receive anti-amyloid- β monoclonal antibody treatment options
- List common adverse effects of anti-amyloid- β monoclonal antibodies for Alzheimer's disease

Speaker Bio:

Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP serves as the Professor and Dean of the Pacific University School of Pharmacy in Hillsboro, Oregon. She is a Board-Certified Psychiatric and Geriatric Pharmacist, as well as a Fellow of the American Society of Consultant Pharmacists (ASCP). She holds an M.S. (Pharm), Pharm.D., and a Ph.D. in Pathological Neurobiochemistry from Charles University in the Czech Republic, along with a Ph.D. in Neuropharmacology from the University of Eastern Finland. She also completed a medical research fellowship in neuropharmacology at Vanderbilt University School of Medicine and a Parkinson's disease traineeship at Northwestern University.

Her clinical expertise lies in geriatrics and neuropsychiatry, and she has extensive experience practicing in both inpatient and outpatient team-based clinical settings. Since 2013, she has served on the editorial board of *Continuum: Lifelong Learning in Neurology* (published by the American Academy of Neurology) and acts as a clinical pharmacy specialist consultant in neurology and psychiatry for Lexicomp, Wolters Kluwer. As a clinician, educator, and scholar, Dr. Marvanova is deeply committed to advancing training in geriatrics and neuropsychiatry while working to improve health outcomes for older adults.